HC Wainwright Lowers Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $10.00

Key Points

• HC Wainwright has lowered its price target for Black Diamond Therapeutics (NASDAQ:BDTX) from $12.00 to $10.00, while still maintaining a "buy" rating, indicating a potential upside of 316.67% from the current price.
• Recent evaluations from other brokerages include a downgrade from Wall Street Zen to a "hold" rating, while Raymond James Financial has raised the stock to "outperform" with a price target of $11.00.
• Black Diamond Therapeutics reported earnings of ($0.19) EPS for the quarter, exceeding analyst expectations of ($0.25), with a consensus rating of "Moderate Buy" and a target price of $12.40.

Black Diamond Therapeutics (NASDAQ:BDTX - Free Report) had its price target trimmed by HC Wainwright from $12.00 to $10.00 in a research report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at $0.33 EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($1.04) EPS.

Several other equities research analysts also recently weighed in on the stock. Raymond James Financial upgraded shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 target price for the company in a research note on Tuesday, July 1st. Wall Street Zen cut Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Black Diamond Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $12.40.

Black Diamond Therapeutics Stock Performance

Black Diamond Therapeutics stock traded up $0.02 during trading hours on Monday, hitting $2.79. The company had a trading volume of 1,079,040 shares, compared to its average volume of 2,012,187. The firm has a market cap of $158.86 million, a P/E ratio of 12.13 and a beta of 2.87. The company has a 50-day moving average price of $2.64 and a two-hundred day moving average price of $2.15. Black Diamond Therapeutics has a 1 year low of $1.20 and a 1 year high of $6.75.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.06. As a group, equities research analysts anticipate that Black Diamond Therapeutics will post -1.3 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in shares of Black Diamond Therapeutics in the second quarter worth about $1,830,000. Tang Capital Management LLC lifted its holdings in Black Diamond Therapeutics by 51.1% in the fourth quarter. Tang Capital Management LLC now owns 2,070,209 shares of the company's stock valued at $4,430,000 after acquiring an additional 700,000 shares during the period. Renaissance Technologies LLC lifted its holdings in Black Diamond Therapeutics by 256.2% in the fourth quarter. Renaissance Technologies LLC now owns 904,000 shares of the company's stock valued at $1,935,000 after acquiring an additional 650,200 shares during the period. Vestal Point Capital LP boosted its position in Black Diamond Therapeutics by 11.4% in the 4th quarter. Vestal Point Capital LP now owns 5,600,000 shares of the company's stock worth $11,984,000 after purchasing an additional 571,500 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Black Diamond Therapeutics during the 4th quarter worth approximately $1,197,000. Hedge funds and other institutional investors own 95.47% of the company's stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.